North America Diltiazem Market Size and Competitive Analysis by 2028

The North America diltiazem market is expected to reach US$ 369.22 million by 2028 from US$ 161.53 million in 2021; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028.

Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The Centers for Disease Control and Prevention (CDC) estimated that around 2.7–6.1 million people were suffering from Atrial fibrillation (AFib) in the US in 2019. Every year, over 454,000 hospitalizations and about 158,000 deaths are reported due to AFib in the US. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.

Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.

In North America, the US was highly influenced by the eruption of the COVID-19 pandemic. The COVID-19 pandemic has created technological shifts crucial to providing better care. Given the current pandemic and the need for practicality, the drugs should ideally be FDA approved so they can be rapidly repurposed for COVID-19 treatment. SARS-CoV requires Ca2+ ions for host cell entrance, and based on the connection between SARS-CoV and SARS-CoV-2, it is very likely that the exact necessities exist for both viruses. Moreover, as per the recent report of bioRxiv published in July 2020, there is evidence that calcium channel blockers (CCB) inhibit viral infections at the cell entry level. Therefore, treatment with verapamil or Diltiazem inhibits viral infection. Hypertension was among the general comorbidities seen in COVID-19 infected patients. Diltiazem may be helpful to treat hypertension associated with COVID-19. Since the COVID-19 outbreak reached the pandemic status, the entire global supply chain has been affected; however, various pharmaceutical companies are developing vaccines and drugs to combat the pandemic. Therefore, COVID-19 has had a substantial positive impact on the diltiazem market.

NORTH AMERICA DILTIAZEM MARKET SEGMENTATION

By Product Type

• Tablet
• Capsules
• Injection

By Application

• Hypertension
• Angina
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd
• MYLAN N.V.
• Pfizer Inc.
• Sandoz (Novartis AG)
• Sun Pharmaceutical Industries Ltd
• Hikma Pharmaceuticals PLC
• Zydus Cadila
• Glenmark
• Athenex

North America Diltiazem Report Scope